EUVIMEDEUVIMED entdecken
Crossref

Astaxanthin Augmented the Anti‐Hepatocellular Carcinoma Efficacy of Sorafenib Through the Inhibition of the JAK2/STAT3 Signaling Pathway and Mitigation of Hypoxia within the Tumor Microenvironment

Pengfei Ren, Qingjuan Tang iD, Xinjia He, Jie Xu iD, Yuming Wang iD, Changhu Xue

Molecular Nutrition & Food Research · 2024

DOI: 10.1002/mnfr.202300569 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Nutrition & Food Research, 2024. Verfasst von Pengfei Ren und 5 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Marine Food Processing & Safety Control, College of Food Science and Engineering, Ocean University of China, Qingdao, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents, STAT3 Transcription Factor. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Scope The optimization of anti‐cancer drug effectiveness through dietary modifications has garnered significant attention among researchers in recent times. Astaxanthin (AST) has been identified as a safe and biologically active dietary supplement. Methods and results The tumor‐bearing mice are treated with sorafenib, along with supplementation of 60 mg kg −1 AST during the treatment. The coadministration of AST and a subclinical dosage of 10 mg kg −1 sorafenib demonstrates a tumor inhibition rate of 76.5%, which is notably superior to the 45% inhibition rate observed with the clinical dosage of 30 mg kg −1 sorafenib ( p < 0.05). The administration of AST leads to a tumor inhibition increase of around 25% when combined with the clinical dose of 30 mg kg −1 sorafenib ( p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntineoplastic AgentsSTAT3 Transcription FactorHumansMiceAnimalsSorafenibTumor MicroenvironmentPhenylurea CompoundsCell Line, TumorSignal TransductionApoptosisHypoxiaNiacinamideJanus Kinase 2Xanthophylls

Stichwörter der Autor:innen

astaxanthindietary supplementationhepatocellular carcinomasensitizing effectsorafenib

Substanzen

SorafenibastaxanthinePhenylurea CompoundsAntineoplastic AgentsNiacinamideJAK2 protein, humanJanus Kinase 2STAT3 protein, humanXanthophyllsSTAT3 Transcription Factor

Autor:innen und Institutionen

  • State Key Laboratory of Marine Food Processing & Safety Control, College of Food Science and Engineering, Ocean University of China, Qingdao, China.
  • Department of Radiation Oncology, The Affiliated Hospital of Qingdao University, Qingdao, China.

ORCID-Profile: Qingjuan Tang, Jie Xu, Yuming Wang

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Ren, P., Tang, Q., He, X., Xu, J., Wang, Y., & Xue, C. (2024). Astaxanthin Augmented the Anti‐Hepatocellular Carcinoma Efficacy of Sorafenib Through the Inhibition of the JAK2/STAT3 Signaling Pathway and Mitigation of Hypoxia within the Tumor Microenvironment. Molecular Nutrition & Food Research. https://doi.org/10.1002/mnfr.202300569

Vancouver

Ren P, Tang Q, He X, Xu J, Wang Y, Xue C. Astaxanthin Augmented the Anti‐Hepatocellular Carcinoma Efficacy of Sorafenib Through the Inhibition of the JAK2/STAT3 Signaling Pathway and Mitigation of Hypoxia within the Tumor Microenvironment. Molecular Nutrition & Food Research. 2024. doi:10.1002/mnfr.202300569

BibTeX
@article{Ren2024,
  author = {Ren, Pengfei and Tang, Qingjuan and He, Xinjia and Xu, Jie and Wang, Yuming and Xue, Changhu},
  title = {Astaxanthin Augmented the Anti‐Hepatocellular Carcinoma Efficacy of Sorafenib Through the Inhibition of the JAK2/STAT3 Signaling Pathway and Mitigation of Hypoxia within the Tumor Microenvironment},
  journal = {Molecular Nutrition & Food Research},
  year = {2024},
  doi = {10.1002/mnfr.202300569}
}
Kostenlos starten →